Lead Product(s) : FXR314
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Organovo Holdings
Deal Size : $60.0 million
Deal Type : Acquisition
Lilly Pays $10M Upfront for Organovo’s FXR Agonist Program
Details : Through the acquisition, Lilly will leverage FXR program of Organovo, which includes FXR314, it is being evaluated for the treatment of Inflammatory Bowel Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $10.0 million
February 25, 2025
Lead Product(s) : FXR314
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Organovo Holdings
Deal Size : $60.0 million
Deal Type : Acquisition
Lead Product(s) : MORF-057
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Morphic Therapeutic
Deal Size : $3,200.0 million
Deal Type : Acquisition
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Details : The acquisition expands Lilly's immunology pipeline with MORF-057, a selective oral small molecule inhibitor of α4β7 integrin for the treatment of inflammatory bowel disease (IBD).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $3,200.0 million
July 08, 2024
Lead Product(s) : MORF-057
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Morphic Therapeutic
Deal Size : $3,200.0 million
Deal Type : Acquisition
Reset All
